rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2020-123-132rsp-2866Research ArticleПЕРЕДОВАЯLEADING ARTICLEКоронавирусная болезнь 2019 (COVID-19): размышления ревматологаCORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTShttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.
115522, Москва, Каширское шоссе, 34А
2119991, Москва, ул. Трубецкая, 8, стр. 2
34A, Kashirskoe Shosse, Moscow 115522
8, Trubetskaya St., Build. 2, Moscow 119991
nasonov@irramn.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation202024042020582123132Copyright © Насонов Е.Л., 20202020Насонов Е.Л.Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2866COVID-19SARS-Cov-2острый респираторный дистресс-синдромиммуновоспалительные ревматические заболеванияCOVID-19SARS-CoV-2acute respiratory distress syndromeimmune-mediated oinflammatory rheumatic diseasesReferencesRichman DD, Whitley RJ, Hayden FG. Clinical Virology. 4th ed. Washington: ASM Press; 2016.Richman DD, Whitley RJ, Hayden FG. Clinical Virology. 4th ed. Washington: ASM Press; 2016.Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8:S9-14. doi: 10.1046/j.1440-1843.2003.00518.xChan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8:S9-14. doi: 10.1046/j.1440-1843.2003.00518.xMiddle East Respiratory Syndrome Coronavirus. Available at: https://www.who.int/emergencies/mers-cov/en/ (accessed 16.02.2020).Middle East Respiratory Syndrome Coronavirus. Available at: https://www.who.int/emergencies/mers-cov/en/ (accessed 16.02.2020).Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020 Jan 16. doi: 10.1002/jmv.25678Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020 Jan 16. doi: 10.1002/jmv.25678WHO Coronavirus disease 2019 (COVID-19) situation report – 52. Available at: https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2WHO Coronavirus disease 2019 (COVID-19) situation report – 52. Available at: https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. doi: 10.1016/S0140-6736(20)30251-8Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. doi: 10.1016/S0140-6736(20)30251-8WHO. Coronavirus disease (COVID-2019) situation reports. 2020. Available at: https://www.who.int/emergencies/diseases/novelcoronavirus-2019/situation-reports (accessed 05.03.2020).WHO. Coronavirus disease (COVID-2019) situation reports. 2020. Available at: https://www.who.int/emergencies/diseases/novelcoronavirus-2019/situation-reports (accessed 05.03.2020).Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronaviruses: the species and its virus – a statement of the Coronavirus Study Group. bioRvxiv. 2020 Feb 11. doi: 10.1101/2020.02.07.937862Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronaviruses: the species and its virus – a statement of the Coronavirus Study Group. bioRvxiv. 2020 Feb 11. doi: 10.1101/2020.02.07.937862Smatti MK, Cyprian FS, Nasrallah GK, et al. Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms. Viruses. 2019;11(8). pii: E762. doi: 10.3390/v11080762Smatti MK, Cyprian FS, Nasrallah GK, et al. Viruses and autoimmunity: A review on the potential interaction and molecular mechanisms. Viruses. 2019;11(8). pii: E762. doi: 10.3390/v11080762Joo YB, Lim YH, Kim KJ, et al. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):199. doi: 10.1186/s13075-019-1977-9Joo YB, Lim YH, Kim KJ, et al. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):199. doi: 10.1186/s13075-019-1977-9Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32. doi: 10.1002/jmv.25685Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32. doi: 10.1002/jmv.25685Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32-52. doi: 10.1038/s41584-019-0337-0Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32-52. doi: 10.1038/s41584-019-0337-0Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. doi: 10.1016/S0140-6736(20)30183-5Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. doi: 10.1016/S0140-6736(20)30183-5Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 (pub. online 2020 March 3). doi: 10.1007/s00134-020-05991-xRuan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 (pub. online 2020 March 3). doi: 10.1007/s00134-020-05991-xChen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):P507-13. doi: 10.1016/S0140-6736(20)30211-7Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):P507-13. doi: 10.1016/S0140-6736(20)30211-7Lei C, Huigo L, Wei L, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Tuberc Respir Dis. 2020 Feb;43:E005.Lei C, Huigo L, Wei L, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Tuberc Respir Dis. 2020 Feb;43:E005.Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi: 10.1001/jama.2020.1585Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi: 10.1001/jama.2020.1585Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Feb 24. doi: 10.1016/S1473-3099(20)30086-4Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Feb 24. doi: 10.1016/S1473-3099(20)30086-4Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29. doi: 10.1186/s40249-020-00646-xAdhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29. doi: 10.1186/s40249-020-00646-xHe F, Deng Y, Li W. Coronavirus Disease 2019 (COVID-19): What we know? J Med Virol. 2020 Mar 14. doi: 10.1002/jmv.25766He F, Deng Y, Li W. Coronavirus Disease 2019 (COVID-19): What we know? J Med Virol. 2020 Mar 14. doi: 10.1002/jmv.25766Li LQ, Huang T, Wang YQ, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of metaanalysis. J Med Virol. 2020 Mar 12. doi: 10.1002/jmv.25757Li LQ, Huang T, Wang YQ, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of metaanalysis. J Med Virol. 2020 Mar 12. doi: 10.1002/jmv.25757Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020 Mar 3:102434. doi: 10.1016/j.jaut.2020.102434Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020 Mar 3:102434. doi: 10.1016/j.jaut.2020.102434Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al.; Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Electronic address: https://www.lancovid.org. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar 13:101623. doi: 10.1016/j.tmaid.2020.101623Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al.; Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Electronic address: https://www.lancovid.org. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar 13:101623. doi: 10.1016/j.tmaid.2020.101623Xu Z, Shi L, Wang Y, et al. Pathological finding of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. (Pub. Feb 18, 2020). doi: 10.1016/S2213-2600(20)30076-XXu Z, Shi L, Wang Y, et al. Pathological finding of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. (Pub. Feb 18, 2020). doi: 10.1016/S2213-2600(20)30076-XTian S, Hu W, Niu L, et al. Pulmonary pathology of erarly phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020. doi: 10.20944/preprints202002.0220.v2Tian S, Hu W, Niu L, et al. Pulmonary pathology of erarly phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020. doi: 10.20944/preprints202002.0220.v2Fung SY, Yuen KS, Ye ZW, et al. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020 Mar 14;9(1):558-70. doi: 10.1080/22221751.2020.1736644Fung SY, Yuen KS, Ye ZW, et al. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020 Mar 14;9(1):558-70. doi: 10.1080/22221751.2020.1736644Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18. doi: 10.1038/s41572-019-0069-0Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18. doi: 10.1038/s41572-019-0069-0Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 2020 Mar 21. doi: 10.1161/CIRCULATIONAHA.120.046941Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 2020 Mar 21. doi: 10.1161/CIRCULATIONAHA.120.046941Yang J, Sheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systemic reviews and meta-analysis. Int J Infect Dis. 2020. doi: 10.1016/J.ijid.2020.03.017Yang J, Sheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systemic reviews and meta-analysis. Int J Infect Dis. 2020. doi: 10.1016/J.ijid.2020.03.017Гордеев АВ, Галушко ЕА, Насонов ЕЛ. Концепция мультиморбидности в ревматологической практике. Научно-практическая ревматология. 2014;52(4):362-5. doi: 10.14412/1995-4484-2014-362-365Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):362-5. doi: 10.14412/1995-4484-2014-362-365 (In Russ.)Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol. 2019;15(8):461-74. doi: 10.1038/s41584-019-0256-0Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol. 2019;15(8):461-74. doi: 10.1038/s41584-019-0256-0Arrossi AV. Pulmonary Pathology in Rheumatic Disease. Clin Chest Med. 2019;40(3):667-77. doi: 10.1016/j.ccm.2019.05.011Arrossi AV. Pulmonary Pathology in Rheumatic Disease. Clin Chest Med. 2019;40(3):667-77. doi: 10.1016/j.ccm.2019.05.011Antin-Ozerkis D, Hinchcliff M. Connective tissue disease-associated interstitial lung disease: evaluation and management. Clin Chest Med. 2019;40(3):617-36. doi: 10.1016/j.ccm.2019.05.008Antin-Ozerkis D, Hinchcliff M. Connective tissue disease-associated interstitial lung disease: evaluation and management. Clin Chest Med. 2019;40(3):617-36. doi: 10.1016/j.ccm.2019.05.008Панафидина ТА, Кондратьева ЛВ, Герасимова ЕВ и др. Коморбидность при ревматоидном артрите. Научно-практическая ревматология. 2014;52(3):283-9. doi: 10.14412/1995-4484-2014-283-289Panafidina TA, Kondratyeva LV, Gerasimova EV, et al. Comorbidity in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):283-9. doi: 10.14412/1995-4484-2014-283-289 (In Russ.)Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus [2019-nCoV] infected pneumonia. Mil Med Res. 2020;7:4. doi: 10.1186/s40779-020-0233-6Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus [2019-nCoV] infected pneumonia. Mil Med Res. 2020;7:4. doi: 10.1186/s40779-020-0233-6Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020. doi: org/10.1515/ccim-2020-0198Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020. doi: org/10.1515/ccim-2020-0198Lippi G. Sepsis biomarkers: past present and future. Clin Chem Lab Med. 2019;57:1281-3. doi: 10.1515/cclm-2018-1347Lippi G. Sepsis biomarkers: past present and future. Clin Chem Lab Med. 2019;57:1281-3. doi: 10.1515/cclm-2018-1347Белов БС, Тарасова ГМ, Муравьева НВ. Роль биомаркеров в диагностике бактериальных инфекций при ревматических заболеваниях. Научно-практическая ревматология. 2019;57(3):333-8. doi: 10.14412/1995-4484-2019-333-338Belov BS, Tarasova GM, Muravyeva NV. Role of biomarkers in the diagnosis of bacterial infections in rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):333-8. doi: 10.14412/1995-4484-2019-333-338 (In Russ.)Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 Mar 16. doi: 10.1515/cclm-2020-0188Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 Mar 16. doi: 10.1515/cclm-2020-0188Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Feb 19. doi: 10.1111/jth.14768Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Feb 19. doi: 10.1111/jth.14768Lippi G, Plebani M, Michael Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020 Mar 13. doi: 10.1016/j.cca.2020.03.022Lippi G, Plebani M, Michael Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020 Mar 13. doi: 10.1016/j.cca.2020.03.022Li T. Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Emerg Microbes Infect. 2020 Mar 14;9(1):582-5. doi: 10.1080/22221751.2020.1735265Li T. Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Emerg Microbes Infect. 2020 Mar 14;9(1):582-5. doi: 10.1080/22221751.2020.1735265Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. Emerg Microbes Infect. 2020 Mar 20:1-26. doi: 10.1080/22221751.2020.1745095Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. Emerg Microbes Infect. 2020 Mar 20:1-26. doi: 10.1080/22221751.2020.1745095Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020 Mar 16. doi: 10.1515/cclm-2020-0285Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020 Mar 16. doi: 10.1515/cclm-2020-0285Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020. doi: 10.1148/radio.2020200230Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020. doi: 10.1148/radio.2020200230Huang O, Liu T, Huang L, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology. 2020. doi: 10.1148/radiol.2020200330Huang O, Liu T, Huang L, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology. 2020. doi: 10.1148/radiol.2020200330Xie X, Zghong Z, Zhao M, et al. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. 2020. doi: 10.1148/radiol.2020200343Xie X, Zghong Z, Zhao M, et al. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. 2020. doi: 10.1148/radiol.2020200343Tao Ai, Zhenlu Yang, Hongyan Hou, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020;200642. doi: 10.1148/radiol.2020200642Tao Ai, Zhenlu Yang, Hongyan Hou, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020;200642. doi: 10.1148/radiol.2020200642Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 2020 Mar 10:200823. doi: 10.1148/radiol.2020200823Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 2020 Mar 10:200823. doi: 10.1148/radiol.2020200823Yan Li, Liming Xia Coronavirus disease 2019 (COVID-19): Role of Chest CT in diagnosis and management. Am J Roentgen: 1-7. doi: 10.2214/AJR.20.22954Yan Li, Liming Xia Coronavirus disease 2019 (COVID-19): Role of Chest CT in diagnosis and management. Am J Roentgen: 1-7. doi: 10.2214/AJR.20.22954Han R, Huang L, Jiang H, et al. Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. AJR Am J Roentgenol. 2020 Mar 17:1-6. doi: 10.2214/AJR.20.22961Han R, Huang L, Jiang H, et al. Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. AJR Am J Roentgenol. 2020 Mar 17:1-6. doi: 10.2214/AJR.20.22961Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related coronavirus diseases. ACS Cent Sci. 2020. doi: 10.1021/acscentsci.0c00272Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related coronavirus diseases. ACS Cent Sci. 2020. doi: 10.1021/acscentsci.0c00272Dhama K, Sharun K, Tiwari R, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020 Mar 18:1-7. doi: 10.1080/21645515.2020.1735227Dhama K, Sharun K, Tiwari R, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020 Mar 18:1-7. doi: 10.1080/21645515.2020.1735227Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-39. doi: 10.1007/s00281-017-0629-xChannappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-39. doi: 10.1007/s00281-017-0629-xSchrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-66. doi: 10.1038/s41584-020-0372-xSchrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-66. doi: 10.1038/s41584-020-0372-xНасонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-61. doi: 10.14412/1995-4484-2019-452-461Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: new evidence. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(4):452-61. doi: 10.14412/1995-4484-2019-452-461 (In Russ.)Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infection in the 21st century. Int J Antimicrob Agents. 2007;30:297-308.Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infection in the 21st century. Int J Antimicrob Agents. 2007;30:297-308.Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 11:105938. doi: 10.1016/j.ijantimicag.2020.105938Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 11:105938. doi: 10.1016/j.ijantimicag.2020.105938Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol. 2001;20:137-40. doi: 10.1016/S1386-6532(00)00140-2Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol. 2001;20:137-40. doi: 10.1016/S1386-6532(00)00140-2Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71. doi: 10.1038/s41422-020-0282-0Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71. doi: 10.1038/s41422-020-0282-0Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Feb. doi: 10.5582/bst.2020.01047Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Feb. doi: 10.5582/bst.2020.01047Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Mar 20. doi: 10.1093/jac/dkaa114Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Mar 20. doi: 10.1093/jac/dkaa114Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Mar 10. doi: 10.1016/j.jcrc.2020.03.005Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Mar 10. doi: 10.1016/j.jcrc.2020.03.005Russell CD, Millar JE, Baillie JK. Clinical evidence does not suppot corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473-5. doi: 10.1016/S0140-6736(20)30317-2Russell CD, Millar JE, Baillie JK. Clinical evidence does not suppot corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473-5. doi: 10.1016/S0140-6736(20)30317-2Ni Y-N, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23:99. doi: 10.1186/s13054-019-2395-8Ni Y-N, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23:99. doi: 10.1186/s13054-019-2395-8Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-allrounders tackling the versatile players of the immune system. Front Immunol. 2019 Jul 24;10:1744. doi: 10.3389/fimmu.2019.01744. eCollection 2019.Strehl C, Ehlers L, Gaber T, Buttgereit F. Glucocorticoids-allrounders tackling the versatile players of the immune system. Front Immunol. 2019 Jul 24;10:1744. doi: 10.3389/fimmu.2019.01744. eCollection 2019.Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic disease. Nat Rev Rheumatol. 2020. doi: 10.1038/s415840020-0371-yHardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic disease. Nat Rev Rheumatol. 2020. doi: 10.1038/s415840020-0371-yCain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017. doi: 10.1038/nri2017.1Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017. doi: 10.1038/nri2017.1Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457-65. doi: 10.1517/14740338.2016.1140743Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457-65. doi: 10.1517/14740338.2016.1140743Heming N, Sivanandamoorthy S, Meng P, et al. Immune effects of corticosteroids in sepsis. Front Immunol. 2018;9:1736. doi: 10.3389/fimmu.2018.01736Heming N, Sivanandamoorthy S, Meng P, et al. Immune effects of corticosteroids in sepsis. Front Immunol. 2018;9:1736. doi: 10.3389/fimmu.2018.01736Rygard SL, Butler E, Granholm A, et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018 Jul;44(7):1003-16. doi: 10.1007/s00134-018-5197-6Rygard SL, Butler E, Granholm A, et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018 Jul;44(7):1003-16. doi: 10.1007/s00134-018-5197-6Meduri GU, Bridges L, Shih MC, et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and triallevel meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829-40. doi: 10.1007/s00134-015-4095-4Meduri GU, Bridges L, Shih MC, et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and triallevel meta-analysis of the updated literature. Intensive Care Med. 2016;42(5):829-40. doi: 10.1007/s00134-015-4095-4Chan ED, Chan MM, Chan MM, Marik PE. Use of glucocorticoids in the critical care setting: Science and clinical evidence. Pharmacol Ther. 2020;206:107428. doi: 10.1016/j.pharmthera.2019.107428Chan ED, Chan MM, Chan MM, Marik PE. Use of glucocorticoids in the critical care setting: Science and clinical evidence. Pharmacol Ther. 2020;206:107428. doi: 10.1016/j.pharmthera.2019.107428Arabi YM, Mandouran Y, Al-Hameed F, et al. Glucocosteroid therapy for critically ill parients with middle east respiratory syndrome. Am J Resp Crit Care Med. 2018;197L757-767. doi: 10.1164/rccm.201706-1172OCArabi YM, Mandouran Y, Al-Hameed F, et al. Glucocosteroid therapy for critically ill parients with middle east respiratory syndrome. Am J Resp Crit Care Med. 2018;197L757-767. doi: 10.1164/rccm.201706-1172OCPeiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak or coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-72. doi: 10.1016/S0140-6736(03)13412-5Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak or coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-72. doi: 10.1016/S0140-6736(03)13412-5Zhou Y-H, Qin Y-Y, Lu Y-Q, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J. 2020. doi: 10.1097/CM9/ 0000000000000791Zhou Y-H, Qin Y-Y, Lu Y-Q, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J. 2020. doi: 10.1097/CM9/ 0000000000000791WHO. Clinical management of severe acute respiratory infection when novel coronavirus [nCoV] infection is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-[ncov]-infection-is-suspected (accessed 09.02.2020).WHO. Clinical management of severe acute respiratory infection when novel coronavirus [nCoV] infection is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-[ncov]-infection-is-suspected (accessed 09.02.2020).Behrens EM, Koretzky GA. Review: Cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheum. 2017;69(6):1135-43. doi: 10.1002/art.40071Behrens EM, Koretzky GA. Review: Cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheum. 2017;69(6):1135-43. doi: 10.1002/art.40071Gupta KK, Khan MA, Singh SK. Constitutive inflammatory cytokine storm: a major threat to human health. J Interferon Cytokine Res. 2020;40(1):19-23. doi: 10.1089/jir.2019.0085Gupta KK, Khan MA, Singh SK. Constitutive inflammatory cytokine storm: a major threat to human health. J Interferon Cytokine Res. 2020;40(1):19-23. doi: 10.1089/jir.2019.0085Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383:1503-16. doi: 10.1016/S0140-6736(13)61048-XRamos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383:1503-16. doi: 10.1016/S0140-6736(13)61048-XCrayne CB, Albeituni S, Nichols KE, Cron RQ. The Immunology of Macrophage Activation Syndrome. Front Immunol. 2019 Feb 1;10:119. doi: 10.3389/fimmu.2019.00119Crayne CB, Albeituni S, Nichols KE, Cron RQ. The Immunology of Macrophage Activation Syndrome. Front Immunol. 2019 Feb 1;10:119. doi: 10.3389/fimmu.2019.00119Karakike E, Giamarellos-Bourboulis EJ. Macrophage activationlike syndrome: a distinct entity leading to early death in sepsis. Front Immunol. 2019 Jan 31;10:55. doi: 10.3389/fimmu.2019.00055Karakike E, Giamarellos-Bourboulis EJ. Macrophage activationlike syndrome: a distinct entity leading to early death in sepsis. Front Immunol. 2019 Jan 31;10:55. doi: 10.3389/fimmu.2019.00055Shimabukuro-Vornhagen A, Gö del P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi: 10.1186/s40425-018-0343-9Shimabukuro-Vornhagen A, Gö del P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi: 10.1186/s40425-018-0343-9Wu D, Yang XO. Th17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. J Microb Immun Infect. 2020. doi: 1016/j.jmii.2020.03.005Wu D, Yang XO. Th17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. J Microb Immun Infect. 2020. doi: 1016/j.jmii.2020.03.005Faure E, Poissy J, Goffard C, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside. PLoS One. 2014;9:e88776. doi: 10.1371/journal.pone.0088716Faure E, Poissy J, Goffard C, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside. PLoS One. 2014;9:e88776. doi: 10.1371/journal.pone.0088716Josset L, Menachery VD, Graliski LE, et al. Cell host response to infection with novel human coronavirus EMC predict potential antiviral and important differences with SARS coronavirus. mBio. 2013;4:e00165-00113. doi: 10.1128/mBio.00165-13Josset L, Menachery VD, Graliski LE, et al. Cell host response to infection with novel human coronavirus EMC predict potential antiviral and important differences with SARS coronavirus. mBio. 2013;4:e00165-00113. doi: 10.1128/mBio.00165-13Bermejo-Martin JE, Ortiz de Lejarazu R, Pumarola T, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009;13:R201. doi: 10.1186/cc8208Bermejo-Martin JE, Ortiz de Lejarazu R, Pumarola T, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009;13:R201. doi: 10.1186/cc8208Zhou Y, Fu B, Zheng X, et al. Abberant pathogenic GM-CSF+T cells and inflammatory CD14+CD16+ monocyte in severe pulmonary syndrome patients of a new coronavirus. bioRxiv. 2020. doi: 10.1101/2020.02.12.945576Zhou Y, Fu B, Zheng X, et al. Abberant pathogenic GM-CSF+T cells and inflammatory CD14+CD16+ monocyte in severe pulmonary syndrome patients of a new coronavirus. bioRxiv. 2020. doi: 10.1101/2020.02.12.945576Liu T, Zhang J, Yang Y, et al. The potential role of interleukin 6 in monitoring severe case of coronavirus disesase. MedRxiv. 2020. doi: 10.1101/2020/03/01/20029769Liu T, Zhang J, Yang Y, et al. The potential role of interleukin 6 in monitoring severe case of coronavirus disesase. MedRxiv. 2020. doi: 10.1101/2020/03/01/20029769Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25770Liu T, Zhang J, Yang Y, et al. The potential role of interleukin 6 in monitoring severe case of coronavirus disesase. MedRxiv. 2020. doi: 10.1101/2020/03/01/20029769Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial. Crit Care Med. 2016;44:275-81. doi: 10.1097/CCM.0000000000001402Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25770Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheum. 2020 Feb;72(2):326-34. doi: 10.1002/art.41103Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25770Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-9. doi: 10.14412/1995-4484-2017-590-599Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial. Crit Care Med. 2016;44:275-81. doi: 10.1097/CCM.0000000000001402Koch C, Barrett D, Teachey T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Exp Rev Clin Immunol. 2019;15:813-22. doi: 10.1080/1744666X.2019.1629904Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial. Crit Care Med. 2016;44:275-81. doi: 10.1097/CCM.0000000000001402Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2019;24(6):739-48. doi: 10.1038/s41591-018-0036-4Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheum. 2020 Feb;72(2):326-34. doi: 10.1002/art.41103Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheum. 2020 Feb;72(2):326-34. doi: 10.1002/art.41103Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cellinduced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731-8. doi: 10.1038/s41591-018-0041-7Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9. doi: 10.14412/1995-4484-2017-590-599 (In Russ.)Xu X, Han M, Sun W, et al. Effective treatment of Severe COVID-19 patients with tocilizumab. ChinaXiv (internet) 2020 Mar 5. Available at: https://ser.es/wpcontent/uploads/2020/03/TCZ-and-COVID-19.pdfNasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):590-9. doi: 10.14412/1995-4484-2017-590-599 (In Russ.)Canna SW, Girard C, Malle L, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139(5):1698-701. doi: 10.1016/j.jaci.2016.10.022Koch C, Barrett D, Teachey T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Exp Rev Clin Immunol. 2019;15:813-22. doi: 10.1080/1744666X.2019.1629904Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019 Jan 8;3(1):47-50. doi: 10.1182/bloodadvances.2018025858Koch C, Barrett D, Teachey T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Exp Rev Clin Immunol. 2019;15:813-22. doi: 10.1080/1744666X.2019.1629904Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16.Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2019;24(6):739-48. doi: 10.1038/s41591-018-0036-4Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2019;24(6):739-48. doi: 10.1038/s41591-018-0036-4Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Bio Rxiv. 2020 (pub. online Jan 26). doi: 10.1101/2020.01.26.919985Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 (pub. online Jan 30). doi: 10.1016/S0140-6736(20)30251-8Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cellinduced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731-8. doi: 10.1038/s41591-018-0041-7Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Feb 27. doi: 10.1016/S1473-3099(20)30132-8Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cellinduced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731-8. doi: 10.1038/s41591-018-0041-7Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 20192019;6(12):e630-e637. doi: 10.1016/S2352-3026(19)30156-5Xu X, Han M, Sun W, et al. Effective treatment of Severe COVID-19 patients with tocilizumab. ChinaXiv (internet) 2020 Mar 5. Available at: https://ser.es/wpcontent/uploads/2020/03/TCZ-and-COVID-19.pdfHenter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. doi: 10.1002/pbc.21039Xu X, Han M, Sun W, et al. Effective treatment of Severe COVID-19 patients with tocilizumab. ChinaXiv (internet) 2020 Mar 5. Available at: https://ser.es/wpcontent/uploads/2020/03/TCZ-and-COVID-19.pdfFardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheum. 2014;66(9):2613-20. doi: 10.1002/art.38690Canna SW, Girard C, Malle L, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139(5):1698-701. doi: 10.1016/j.jaci.2016.10.022Canna SW, Girard C, Malle L, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139(5):1698-701. doi: 10.1016/j.jaci.2016.10.022Canna SW, Girard C, Malle L, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139(5):1698-701. doi: 10.1016/j.jaci.2016.10.022Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019 Jan 8;3(1):47-50. doi: 10.1182/bloodadvances.2018025858Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019 Jan 8;3(1):47-50. doi: 10.1182/bloodadvances.2018025858Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019 Jan 8;3(1):47-50. doi: 10.1182/bloodadvances.2018025858Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019 Jan 8;3(1):47-50. doi: 10.1182/bloodadvances.2018025858Nasonov EL, Lila AM. Janus kinase inhibitors in immunoinflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16 (In Russ.)Nasonov EL, Lila AM. Janus kinase inhibitors in immunoinflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16 (In Russ.)Nasonov EL, Lila AM. Janus kinase inhibitors in immunoinflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16 (In Russ.)Nasonov EL, Lila AM. Janus kinase inhibitors in immunoinflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16 (In Russ.)Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Bio Rxiv. 2020 (pub. online Jan 26). doi: 10.1101/2020.01.26.919985Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Bio Rxiv. 2020 (pub. online Jan 26). doi: 10.1101/2020.01.26.919985Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Bio Rxiv. 2020 (pub. online Jan 26). doi: 10.1101/2020.01.26.919985Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Bio Rxiv. 2020 (pub. online Jan 26). doi: 10.1101/2020.01.26.919985Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 (pub. online Jan 30). doi: 10.1016/S0140-6736(20)30251-8Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 (pub. online Jan 30). doi: 10.1016/S0140-6736(20)30251-8Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 (pub. online Jan 30). doi: 10.1016/S0140-6736(20)30251-8Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 (pub. online Jan 30). doi: 10.1016/S0140-6736(20)30251-8Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Feb 27. doi: 10.1016/S1473-3099(20)30132-8Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Feb 27. doi: 10.1016/S1473-3099(20)30132-8Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Feb 27. doi: 10.1016/S1473-3099(20)30132-8Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Feb 27. doi: 10.1016/S1473-3099(20)30132-8Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 20192019;6(12):e630-e637. doi: 10.1016/S2352-3026(19)30156-5Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 20192019;6(12):e630-e637. doi: 10.1016/S2352-3026(19)30156-5Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 20192019;6(12):e630-e637. doi: 10.1016/S2352-3026(19)30156-5Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 20192019;6(12):e630-e637. doi: 10.1016/S2352-3026(19)30156-5Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. doi: 10.1002/pbc.21039Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. doi: 10.1002/pbc.21039Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. doi: 10.1002/pbc.21039Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. doi: 10.1002/pbc.21039Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheum. 2014;66(9):2613-20. doi: 10.1002/art.38690Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheum. 2014;66(9):2613-20. doi: 10.1002/art.38690Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheum. 2014;66(9):2613-20. doi: 10.1002/art.38690Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheum. 2014;66(9):2613-20. doi: 10.1002/art.38690
The authors declare that there are no conflicts of interest present.